Loading
Calderasib is an experimental small-molecule drug from Merck Sharp & Dohme in phase 3 trials for non-small-cell lung cancer and colorectal cancer, aimed at KRAS.
Calderasib (MK-1084) is a small-molecule drug developed by Merck Sharp & Dohme. Its target is KRAS (the sponsor names KRAS G12C). The sponsor states: MK-1084 is described as an investigational, oral, selective KRAS G12C inhibitor. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07554339 (A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)), NCT06345729 (A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumour Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)) and NCT07431827 (MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)), in non-small-cell lung cancer and colorectal cancer. The largest, NCT07190248, plans to enrol 675 participants with primary completion expected 2029-12-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
MK-1084 is described as an investigational, oral, selective KRAS G12C inhibitor. Connects to KRAS.
1.Calderasib slips into a pocket on KRAS.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Calderasib" OR ABSTRACT:"Calderasib" OR TITLE:"MK-1084" OR ABSTRACT:"MK-1084") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Calderasib, not a curated reading list.
Shares KRAS G12C-mutant non-small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, Merck & Co. (MSD), Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, Merck & Co. (MSD), Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Merck & Co. (MSD), Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.